MD4655C1 - Virusurile bolii de Newcastle şi utilizarea acestora - Google Patents
Virusurile bolii de Newcastle şi utilizarea acestoraInfo
- Publication number
- MD4655C1 MD4655C1 MDA20150100A MD20150100A MD4655C1 MD 4655 C1 MD4655 C1 MD 4655C1 MD A20150100 A MDA20150100 A MD A20150100A MD 20150100 A MD20150100 A MD 20150100A MD 4655 C1 MD4655 C1 MD 4655C1
- Authority
- MD
- Moldova
- Prior art keywords
- antagonist
- newcastle disease
- disease viruses
- cytokine
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Invenţia se referă la metode de tratament al cancerului, care includ administrarea virusurilor bolii de Newcastle (NDV) în combinaţie cu un antagonist al proteinei morţii celulare programate 1 (PD1), care reprezintă un anticorp şi se leagă specific la PD1 şi blochează legarea PD1 cu liganzii săi nativi. De asemenea, invenţia include administrarea unui NDV hibrid în combinaţie cu un antagonist al PD1, în care NDV hibrid conţine un genom ambalat cu conţinut de o secvenţă de nucleotide, care codifică o citokină, în care citokina este exprimată de virus şi antagonistul PD1 reprezintă un anticorp, care se leagă specific la PD1 şi blochează legarea PD1 cu liganzii săi nativi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361782994P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/020299 WO2014158811A1 (en) | 2013-03-14 | 2014-03-04 | Newcastle disease viruses and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
MD20150100A2 MD20150100A2 (ro) | 2016-02-29 |
MD4655B1 MD4655B1 (ro) | 2019-11-30 |
MD4655C1 true MD4655C1 (ro) | 2020-06-30 |
Family
ID=51527979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20150100A MD4655C1 (ro) | 2013-03-14 | 2014-03-04 | Virusurile bolii de Newcastle şi utilizarea acestora |
Country Status (28)
Country | Link |
---|---|
US (5) | US20160015760A1 (ro) |
EP (1) | EP2968525A4 (ro) |
JP (4) | JP6596411B2 (ro) |
KR (1) | KR102222157B1 (ro) |
CN (3) | CN111218429A (ro) |
AP (1) | AP2015008685A0 (ro) |
AU (2) | AU2014241843B2 (ro) |
BR (1) | BR112015021414B1 (ro) |
CA (1) | CA2905272A1 (ro) |
CL (2) | CL2015002532A1 (ro) |
CR (1) | CR20150465A (ro) |
DO (1) | DOP2015000227A (ro) |
EA (1) | EA038981B1 (ro) |
GE (1) | GEP20196976B (ro) |
HK (1) | HK1216618A1 (ro) |
IL (2) | IL241120A0 (ro) |
MA (1) | MA38406B1 (ro) |
MD (1) | MD4655C1 (ro) |
MX (2) | MX2015011886A (ro) |
MY (1) | MY180687A (ro) |
NI (1) | NI201500131A (ro) |
NZ (1) | NZ711946A (ro) |
PE (1) | PE20151921A1 (ro) |
PH (1) | PH12015502087A1 (ro) |
SG (2) | SG11201507412SA (ro) |
TN (1) | TN2015000353A1 (ro) |
WO (1) | WO2014158811A1 (ro) |
ZA (1) | ZA201506192B (ro) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE037460T2 (hu) | 2005-12-02 | 2018-08-28 | Icahn School Med Mount Sinai | Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk |
NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
EP2987856B1 (en) | 2009-02-05 | 2018-07-25 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses and uses thereof |
NZ711946A (en) * | 2013-03-14 | 2020-05-29 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
US10519426B2 (en) * | 2013-09-03 | 2019-12-31 | Medimmune Limited | Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia |
EA035037B1 (ru) | 2013-12-12 | 2020-04-21 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение |
CN107073099B (zh) | 2014-02-27 | 2022-09-27 | 默沙东公司 | 用于治疗癌症的联合方法 |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
AU2015228372B2 (en) | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
CA2955154C (en) | 2014-07-21 | 2023-10-31 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
EP3180359A1 (en) | 2014-08-14 | 2017-06-21 | Novartis AG | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
AU2015317608B2 (en) | 2014-09-17 | 2021-03-11 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
PE20171067A1 (es) | 2014-10-14 | 2017-07-24 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
EP3209382B1 (en) * | 2014-10-24 | 2020-11-25 | Calidi Biotherapeutics, Inc. | Combination immunotherapy approach for treatment of cancer |
US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
CN105985966B (zh) * | 2015-03-06 | 2024-08-16 | 普莱柯生物工程股份有限公司 | 基因vii型新城疫病毒株、其疫苗组合物、制备方法及应用 |
RU2752918C2 (ru) | 2015-04-08 | 2021-08-11 | Новартис Аг | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19 |
GB201509338D0 (en) * | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
US10786547B2 (en) | 2015-07-16 | 2020-09-29 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
EP3317301B1 (en) | 2015-07-29 | 2021-04-07 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
JP6878405B2 (ja) | 2015-07-29 | 2021-05-26 | ノバルティス アーゲー | Pd−1に対する抗体分子を含む組み合わせ治療 |
KR102201147B1 (ko) | 2015-08-11 | 2021-01-11 | 카리디 바이오테라퓨틱스, 인크. | 암 치료에 사용하기 위한 천연두 백신 |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
JP7038065B2 (ja) | 2016-01-08 | 2022-03-17 | レプリミュン リミテッド | 腫瘍溶解性ウイルス株 |
EP3423482A1 (en) | 2016-03-04 | 2019-01-09 | Novartis AG | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
CA3031542A1 (en) | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
JP2020500020A (ja) | 2016-11-14 | 2020-01-09 | ノバルティス アーゲー | 融合誘導性タンパク質minionに関連する組成物、方法、および治療上の使用 |
GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
US11684637B2 (en) | 2017-05-25 | 2023-06-27 | University Of Central Florida Research Foundation, Inc. | Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
SG11202011830SA (en) | 2018-06-13 | 2020-12-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
US20210309744A1 (en) * | 2018-08-29 | 2021-10-07 | Shattuck Labs, Inc. | Combination therapies comprising pd-1-based chimeric proteins |
WO2020069409A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
EP3865141A4 (en) * | 2018-10-09 | 2022-06-08 | Biocomo Incorporation | ANTI-CANCER AGENT, PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND KIT |
CN109627336A (zh) * | 2018-12-20 | 2019-04-16 | 南京昂科利医药科技创新研究院有限公司 | 一种表达pd-l1单链抗体的新城疫溶瘤病毒的制备方法及应用 |
US20230193213A1 (en) * | 2019-01-29 | 2023-06-22 | Arno Thaller | Recombinant oncolytic newcastle disease viruses with increased activity |
EP3938396A1 (en) | 2019-03-11 | 2022-01-19 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
BR112021019328A2 (pt) | 2019-03-29 | 2021-11-30 | Myst Therapeutics Llc | Métodos ex vivo para produzir um produto terapêutico de célula t e composições e métodos relacionados |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
CN110564766A (zh) * | 2019-09-20 | 2019-12-13 | 华农(肇庆)生物产业技术研究院有限公司 | 一种全基因组表达载体pBR322-DHN3的制备方法 |
CN110672844A (zh) * | 2019-10-29 | 2020-01-10 | 华中科技大学 | 一种新城疫病毒抗体磁免疫化学发光检测试剂盒及其应用 |
CN114787188A (zh) | 2019-11-05 | 2022-07-22 | 震动疗法股份有限公司 | 用抗pd-1抗体治疗癌症的方法 |
US11975026B2 (en) | 2019-11-26 | 2024-05-07 | Novartis Ag | CD19 and CD22 chimeric antigen receptors and uses thereof |
CA3162703A1 (en) | 2019-11-27 | 2021-06-03 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
BR112022016490A2 (pt) | 2020-02-27 | 2022-10-11 | Myst Therapeutics Llc | Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas |
US20210386804A1 (en) * | 2020-06-11 | 2021-12-16 | Tibor Bakács | Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients |
US20240033358A1 (en) | 2020-11-13 | 2024-02-01 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
CN115197949A (zh) * | 2021-04-13 | 2022-10-18 | 江苏康缘瑞翱生物医药科技有限公司 | 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途 |
TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Cd19和cd22嵌合抗原受體及其用途 |
KR102476901B1 (ko) | 2021-08-06 | 2022-12-14 | 리벤텍 주식회사 | 대장암 세포 특이적 감염 뉴캐슬병 바이러스를 이용한 대장암 치료용 암용해성 바이러스 및 이를 이용한 대장암 치료용 조성물 |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3922444A1 (de) | 1988-03-01 | 1991-01-10 | Deutsches Krebsforsch | Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen |
DE3806565A1 (de) | 1988-03-01 | 1989-09-14 | Deutsches Krebsforsch | Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
US5786199A (en) | 1989-08-28 | 1998-07-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
PT1314431E (pt) | 1993-04-30 | 2008-10-24 | Wellstat Biologics Corp | Composições purificadas de vírus da doença de newcastle |
PT702085E (pt) | 1994-07-18 | 2004-04-30 | Karl Klaus Conzelmann | Virus de arn de cadeia negativa nao segmentada infeccioso recombinante |
US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
ATE181112T1 (de) | 1995-08-09 | 1999-06-15 | Schweiz Serum & Impfinst | Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren |
CA2230033C (en) | 1995-09-27 | 2010-01-26 | Peter L. Collins | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
US6190901B1 (en) | 1995-10-17 | 2001-02-20 | Wayne State University | Chicken interleukin-15 and uses thereof |
BR9710363A (pt) | 1996-07-15 | 2000-01-11 | Us Gov Health & Human Serv | "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante" |
AU4427897A (en) | 1996-09-27 | 1998-04-17 | American Cyanamid Company | 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales |
CA2291216A1 (en) | 1997-05-23 | 1998-11-26 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
PT1012244E (pt) | 1997-07-11 | 2007-08-21 | Univ Yale | ''rabdovírus com revestimentos remanipulados'' |
AU9389998A (en) | 1997-09-19 | 1999-04-12 | American Cyanamid Company | Attenuated respiratory syncytial viruses |
US7780962B2 (en) | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
ATE371372T1 (de) | 1997-10-09 | 2007-09-15 | Wellstat Biologics Corp | Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren |
US7470426B1 (en) | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
ES2400445T3 (es) | 1998-06-12 | 2013-04-09 | Mount Sinai School Of Medicine | Virus atenuados con cadena de polaridad negativa con actividad antagonista de interferón alterada para uso como vacunas y productos farmacéuticos |
EP0974660A1 (en) | 1998-06-19 | 2000-01-26 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
US7052685B1 (en) | 1998-10-15 | 2006-05-30 | Trustees Of The University Of Pennsylvania | Methods for treatment of cutaneous T-cell lymphoma |
HUP0302278A3 (en) | 1999-04-15 | 2011-01-28 | Pro Virus | Treatment of neoplasms with viruses |
US7244558B1 (en) | 1999-05-05 | 2007-07-17 | University Of Maryland | Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines |
US20030224017A1 (en) | 2002-03-06 | 2003-12-04 | Samal Siba K. | Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors |
ATE353370T1 (de) | 1999-07-14 | 2007-02-15 | Sinai School Medicine | In vitro-rekonstitution von segmentierten, negativstrang-rna-viren |
AU7607900A (en) | 1999-09-22 | 2001-04-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
US6896881B1 (en) | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
JP2003525222A (ja) | 2000-01-20 | 2003-08-26 | ウニベルジテート チューリッヒ インスティチュート フューア メディツィニーチェ ビロロギー | Il−12をコードする核酸分子の腫瘍内投与 |
AU2001257001A1 (en) | 2000-04-10 | 2001-10-23 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
US6818444B2 (en) | 2000-08-04 | 2004-11-16 | Heska Corporation | Canine and feline proteins, nucleic acid molecules and uses thereof |
FR2823222B1 (fr) | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
WO2002102404A1 (en) | 2001-06-18 | 2002-12-27 | Institut National De La Recherche Agronomique | Uses of cytokines |
AU2003223089A1 (en) | 2002-04-29 | 2003-11-17 | Hadasit Medical Research Services And Development Company Ltd. | Compositions and methods for treating cancer with an oncolytic viral agent |
CA2488270A1 (en) | 2002-06-03 | 2003-12-11 | Dnavec Research Inc. | Paramyxoviral vectors encoding antibodies, and uses thereof |
AU2003250575A1 (en) | 2002-08-07 | 2004-02-25 | Mmagix Technology Limited | Apparatus, method and system for a synchronicity independent, resource delegating, power and instruction optimizing processor |
SE0203159D0 (sv) | 2002-10-25 | 2002-10-25 | Electrolux Ab | Handtag till ett motordrivet handhållet verktyg |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
WO2005085282A1 (en) | 2004-02-27 | 2005-09-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity |
NZ581958A (en) | 2004-11-12 | 2011-01-28 | Bayer Schering Pharma Ag | Recombinant newcastle disease virus comprising a transgene encoding a prodrug-converting enzyme or protease for use in the treatment of cancer |
PL3263581T3 (pl) | 2005-05-17 | 2021-05-04 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
US20090214590A1 (en) * | 2005-07-08 | 2009-08-27 | Wayne State University | Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
JP2007120880A (ja) | 2005-10-28 | 2007-05-17 | Mitsubishi Electric Corp | クロスフローファン |
HUE037460T2 (hu) | 2005-12-02 | 2018-08-28 | Icahn School Med Mount Sinai | Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk |
AU2007207785B2 (en) | 2006-01-13 | 2013-11-14 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Codon optimized IL- 15 and IL- 15R-alpha genes for expression in mammalian cells |
EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
US20090175826A1 (en) | 2006-06-05 | 2009-07-09 | Elankumaran Subbiah | Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same |
CA2658584A1 (en) | 2006-07-27 | 2008-01-31 | Ottawa Health Research Institute | Staged immune-response modulation in oncolytic therapy |
ES2654303T3 (es) | 2007-05-04 | 2018-02-13 | University Health Network | Inmunoterapia de IL-12 contra el cáncer |
EP3305805A1 (en) | 2007-05-11 | 2018-04-11 | Altor BioScience Corporation | Fusion molecules and il-15 variants |
NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
NZ599338A (en) | 2007-06-27 | 2013-11-29 | Marinepolymer Tech Inc | Complexes of il-15 and il-15ralpha and uses thereof |
EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
US8313896B2 (en) * | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
WO2010042433A1 (en) * | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
CN101787373B (zh) | 2009-01-23 | 2013-06-19 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种携带外源基因在包装细胞中高效生产的重组病毒载体、其构建方法及其用途 |
EP2987856B1 (en) * | 2009-02-05 | 2018-07-25 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses and uses thereof |
US8556882B2 (en) | 2009-04-30 | 2013-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
US20100297072A1 (en) * | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
AU2010282280B2 (en) | 2009-08-14 | 2016-06-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of IL-15 to increase thymic output and to treat lymphopenia |
PT3210622T (pt) | 2009-08-21 | 2021-03-03 | Univ Georgia | Vacina recombinante contra o paramixovírus aviário e método de preparação e utilização da mesma |
PL2482849T3 (pl) | 2009-09-30 | 2018-11-30 | Memorial Sloan-Kettering Cancer Center | Skojarzona immunoterapia w leczeniu nowotworu |
WO2011119628A2 (en) | 2010-03-23 | 2011-09-29 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
WO2012000188A1 (en) | 2010-06-30 | 2012-01-05 | Tot Shanghai Rd Center Co., Ltd. | Recombinant tumor vaccine and method of producing such |
KR102070098B1 (ko) | 2010-09-21 | 2020-01-28 | 알토 바이오사이언스 코포레이션 | 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법 |
US20120082687A1 (en) * | 2010-10-04 | 2012-04-05 | Alex Wah Hin Yeung | Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use |
WO2012142529A2 (en) | 2011-04-15 | 2012-10-18 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
PL3351261T3 (pl) | 2011-10-11 | 2021-12-06 | Universität Zürich | Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów |
AU2013211871B2 (en) | 2012-01-25 | 2017-12-14 | Board Of Regents, The University Of Texas System | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
EP2669381A1 (en) | 2012-05-30 | 2013-12-04 | AmVac AG | Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein |
WO2014047350A1 (en) | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
NZ630790A (en) | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
NZ711946A (en) | 2013-03-14 | 2020-05-29 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
KR20150145260A (ko) | 2013-04-19 | 2015-12-29 | 싸이튠 파마 | 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료 |
HRP20212023T1 (hr) | 2013-08-08 | 2022-04-01 | Cytune Pharma | Modulokini temeljeni na il-15 i il-15ralpha sushi domeni |
PL3030262T3 (pl) | 2013-08-08 | 2020-07-27 | Cytune Pharma | Złożona kompozycja farmaceutyczna |
US10519426B2 (en) | 2013-09-03 | 2019-12-31 | Medimmune Limited | Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia |
CN107073099B (zh) | 2014-02-27 | 2022-09-27 | 默沙东公司 | 用于治疗癌症的联合方法 |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
EP3174974B1 (en) | 2014-07-29 | 2020-05-20 | Novartis AG | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
SG11201702295UA (en) | 2014-09-22 | 2017-04-27 | Intrexon Corp | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
WO2016094377A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
CN106166294A (zh) | 2015-05-18 | 2016-11-30 | 国科丹蓝生物科技(北京)有限公司 | 一种用于术前介入放疗治疗肿瘤的化合物 |
EP3317301B1 (en) | 2015-07-29 | 2021-04-07 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
JP6878405B2 (ja) | 2015-07-29 | 2021-05-26 | ノバルティス アーゲー | Pd−1に対する抗体分子を含む組み合わせ治療 |
CA3001590A1 (en) | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
BR112018008911A2 (pt) | 2015-11-09 | 2018-11-27 | Immune Design Corp | composições compreendendo vetores lentivirais que expressam il-12 e métodos de uso das mesmas |
JP7038065B2 (ja) | 2016-01-08 | 2022-03-17 | レプリミュン リミテッド | 腫瘍溶解性ウイルス株 |
CN109069624A (zh) | 2016-01-15 | 2018-12-21 | 瑞美控股有限责任公司 | 癌症的免疫治疗 |
US10344067B2 (en) | 2016-02-25 | 2019-07-09 | Deutsches Krebsforschungszentrum | RNA viruses expressing IL-12 for immunovirotherapy |
CN105734023B (zh) | 2016-03-28 | 2019-04-26 | 江苏康缘瑞翱生物医药科技有限公司 | 一种重组新城疫病毒在制备抗肝癌药物中的应用 |
ES2904882T3 (es) | 2016-04-29 | 2022-04-06 | Virogin Biotech Canada Ltd | Vectores de HSV con replicación mejorada en células cancerosas |
-
2014
- 2014-03-04 NZ NZ711946A patent/NZ711946A/en not_active IP Right Cessation
- 2014-03-04 PE PE2015001952A patent/PE20151921A1/es unknown
- 2014-03-04 CN CN202010099385.7A patent/CN111218429A/zh active Pending
- 2014-03-04 BR BR112015021414-2A patent/BR112015021414B1/pt active IP Right Grant
- 2014-03-04 MX MX2015011886A patent/MX2015011886A/es active IP Right Grant
- 2014-03-04 CN CN202010099565.5A patent/CN111172120A/zh active Pending
- 2014-03-04 AP AP2015008685A patent/AP2015008685A0/xx unknown
- 2014-03-04 US US14/774,962 patent/US20160015760A1/en not_active Abandoned
- 2014-03-04 JP JP2016500602A patent/JP6596411B2/ja not_active Expired - Fee Related
- 2014-03-04 MY MYPI2015002047A patent/MY180687A/en unknown
- 2014-03-04 WO PCT/US2014/020299 patent/WO2014158811A1/en active Application Filing
- 2014-03-04 EA EA201591740A patent/EA038981B1/ru unknown
- 2014-03-04 GE GEAP201413952A patent/GEP20196976B/en unknown
- 2014-03-04 AU AU2014241843A patent/AU2014241843B2/en active Active
- 2014-03-04 CN CN201480026748.7A patent/CN105188746B/zh active Active
- 2014-03-04 SG SG11201507412SA patent/SG11201507412SA/en unknown
- 2014-03-04 EP EP14774247.2A patent/EP2968525A4/en active Pending
- 2014-03-04 KR KR1020157027659A patent/KR102222157B1/ko active IP Right Grant
- 2014-03-04 MD MDA20150100A patent/MD4655C1/ro active IP Right Grant
- 2014-03-04 CA CA2905272A patent/CA2905272A1/en active Pending
- 2014-03-04 SG SG10201802982WA patent/SG10201802982WA/en unknown
- 2014-03-04 MA MA38406A patent/MA38406B1/fr unknown
- 2014-03-12 US US14/205,776 patent/US20140271677A1/en not_active Abandoned
-
2015
- 2015-08-18 TN TN2015000353A patent/TN2015000353A1/en unknown
- 2015-08-25 ZA ZA2015/06192A patent/ZA201506192B/en unknown
- 2015-09-03 IL IL241120A patent/IL241120A0/en unknown
- 2015-09-08 CR CR20150465A patent/CR20150465A/es unknown
- 2015-09-08 MX MX2019008086A patent/MX2019008086A/es unknown
- 2015-09-09 DO DO2015000227A patent/DOP2015000227A/es unknown
- 2015-09-09 CL CL2015002532A patent/CL2015002532A1/es unknown
- 2015-09-10 NI NI201500131A patent/NI201500131A/es unknown
- 2015-09-11 PH PH12015502087A patent/PH12015502087A1/en unknown
-
2016
- 2016-04-25 HK HK16104723.8A patent/HK1216618A1/zh unknown
-
2017
- 2017-05-05 US US15/588,251 patent/US20180078592A1/en not_active Abandoned
- 2017-10-20 US US15/789,539 patent/US10251922B2/en active Active
- 2017-10-20 US US15/789,340 patent/US20180256655A1/en not_active Abandoned
-
2018
- 2018-02-26 CL CL2018000515A patent/CL2018000515A1/es unknown
- 2018-09-04 JP JP2018165460A patent/JP2018198621A/ja active Pending
-
2019
- 2019-01-21 IL IL264385A patent/IL264385B/en unknown
- 2019-07-17 AU AU2019206040A patent/AU2019206040A1/en not_active Abandoned
-
2020
- 2020-08-18 JP JP2020137761A patent/JP2020202850A/ja active Pending
-
2022
- 2022-09-28 JP JP2022154392A patent/JP2023002553A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD4655C1 (ro) | Virusurile bolii de Newcastle şi utilizarea acestora | |
CY1121934T1 (el) | Αντισωματα anti-fcrn | |
BR112017006203A2 (pt) | anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune. | |
SG177025A1 (en) | Hepatitis b virus specific antibody and uses thereof | |
MX363533B (es) | Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas. | |
EA201491644A1 (ru) | Фармацевтические композиции | |
CY1122214T1 (el) | Αντισωματα ειδικα για ton fcrn | |
MX2019007921A (es) | Nuevos agentes de union a ha. | |
MX351502B (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
BR112016000303A2 (pt) | partícula tipo viral que compreende antígeno pd-1 ou antígeno ligante pd-1, molécula de ácido nucleico isolada, vetor, composição farmacêutica, uso dos mesmos, e kit | |
CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
TR201903312T4 (tr) | Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. | |
PH12015502164A1 (en) | Flavivirus neutralizing antibodies and methods of use thereof | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
SA517390221B1 (ar) | Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان | |
EA201992687A1 (ru) | Вирусы болезни ньюкасла и их применение | |
NZ722167A (en) | Binding molecules targeting pathogens | |
MY185444A (en) | Enterovirus 71 antiviral peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG4A | Patent for invention issued |